Compare Stocks: YARW, IMRX, EBS, and MYGN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EBS Emergent Biosolutions	$5.67 -5.6%	$6.60	$4.36 ▼ $14.06	$290.46M	2.34	943,730 shs	1.17 million shs
IMRX Immuneering	$4.61 -3.6%	$4.85	$3.86 ▼ $10.08	$298.25M	0.4	1.33 million shs	1.17 million shs
MYGN Myriad Genetics	$3.19 +0.3%	$4.33	$2.74 ▼ $8.59	$305.12M	1.68	1.70 million shs	966,996 shs
YARW Yarrow Bioscience	$29.11 -0.6%	$0.00	$14.17 ▼ $46.95	$77.72M	2.01	14,558 shs	36,599 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EBS Emergent Biosolutions	-3.30%	-2.67%	+23.89%	-27.15%	-20.84%
IMRX Immuneering	-0.83%	-1.44%	+5.99%	+21.94%	-19.66%
MYGN Myriad Genetics	-0.31%	0.00%	-2.45%	-28.22%	-53.98%
YARW Yarrow Bioscience	-3.01%	-5.42%	-29.28%	+2,929,999,900.00%	+2,929,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EBS Emergent Biosolutions	$5.67 -5.6%	$6.60	$4.36 ▼ $14.06	$290.46M	2.34	943,730 shs	1.17 million shs
IMRX Immuneering	$4.61 -3.6%	$4.85	$3.86 ▼ $10.08	$298.25M	0.4	1.33 million shs	1.17 million shs
MYGN Myriad Genetics	$3.19 +0.3%	$4.33	$2.74 ▼ $8.59	$305.12M	1.68	1.70 million shs	966,996 shs
YARW Yarrow Bioscience	$29.11 -0.6%	$0.00	$14.17 ▼ $46.95	$77.72M	2.01	14,558 shs	36,599 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EBS Emergent Biosolutions	-3.30%	-2.67%	+23.89%	-27.15%	-20.84%
IMRX Immuneering	-0.83%	-1.44%	+5.99%	+21.94%	-19.66%
MYGN Myriad Genetics	-0.31%	0.00%	-2.45%	-28.22%	-53.98%
YARW Yarrow Bioscience	-3.01%	-5.42%	-29.28%	+2,929,999,900.00%	+2,929,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EBS Emergent Biosolutions	2.17	Hold	$10.00	76.52% Upside
IMRX Immuneering	3.00	Buy	$17.50	279.61% Upside
MYGN Myriad Genetics	1.57	Reduce	$3.12	-2.19% Downside
YARW Yarrow Bioscience	2.33	Hold	$58.00	99.24% Upside

Current Analyst Ratings Breakdown

Latest YARW, IMRX, EBS, and MYGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/9/2026	EBS Emergent Biosolutions	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00
9/9/2026	MYGN Myriad Genetics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$6.00 ➝ $3.60
9/1/2026	MYGN Myriad Genetics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Underweight	$5.45 ➝ $2.00
8/27/2026	IMRX Immuneering	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/21/2026	EBS Emergent Biosolutions	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Sell (D)
8/21/2026	EBS Emergent Biosolutions	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Underweight
8/18/2026	MYGN Myriad Genetics	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$5.00 ➝ $3.00
8/11/2026	EBS Emergent Biosolutions	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
8/10/2026	EBS Emergent Biosolutions	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$12.00 ➝ $10.00
8/7/2026	EBS Emergent Biosolutions	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/6/2026	IMRX Immuneering	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$14.00

(Data available from 9/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EBS Emergent Biosolutions	$742.30M	0.39	$3.33 per share	1.70	$9.95 per share	0.57
IMRX Immuneering	N/A	N/A	N/A	N/A	$3.38 per share	N/A
MYGN Myriad Genetics	$806.60M	0.38	$3.75 per share	0.85	$3.95 per share	0.81
YARW Yarrow Bioscience	$570K	136.36	N/A	N/A	$41.71 per share	0.70

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EBS Emergent Biosolutions	$52.60M	-$3.55	N/A	7.66	N/A	-22.95%	16.35%	6.17%	11/4/2026 (Estimated)
IMRX Immuneering	-$56.03M	-$1.04	N/A	N/A	N/A	N/A	-27.15%	-25.75%	11/11/2026 (Estimated)
MYGN Myriad Genetics	-$365.90M	-$1.19	N/A	N/A	N/A	-13.96%	-16.09%	-8.10%	11/2/2026 (Estimated)
YARW Yarrow Bioscience	-$26.48M	-$14.64	N/A	N/A	N/A	-4,726.21%	-84.40%	-77.68%	N/A

Latest YARW, IMRX, EBS, and MYGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	YARW Yarrow Bioscience	-$0.18	-$3.51	-$3.33	-$3.51	$0.20 million	$0.10 million
8/5/2026	Q2 2026	EBS Emergent Biosolutions	-$0.0850	$0.60	+$0.6850	-$3.49	$177.50 million	$234.30 million
8/5/2026	Q2 2026	IMRX Immuneering	-$0.2643	-$0.27	-$0.0057	-$0.27	N/A	N/A
7/30/2026	Q2 2026	MYGN Myriad Genetics	-$0.0579	-$0.25	-$0.1921	-$0.46	$206.03 million	$190.70 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
EBS Emergent Biosolutions	N/A	N/A	N/A	N/A	N/A
IMRX Immuneering	N/A	N/A	N/A	N/A	N/A
MYGN Myriad Genetics	N/A	N/A	N/A	N/A	N/A
YARW Yarrow Bioscience	N/A	N/A	N/A	N/A	N/A

Latest YARW, IMRX, EBS, and MYGN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/10/2026	YARW Yarrow Bioscience	special	$19.00			7/22/2026	7/23/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EBS Emergent Biosolutions	1.70	5.42	2.95
IMRX Immuneering	N/A	19.47	19.47
MYGN Myriad Genetics	0.40	2.21	1.98
YARW Yarrow Bioscience	N/A	15.26	15.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EBS Emergent Biosolutions	78.40%
IMRX Immuneering	67.65%
MYGN Myriad Genetics	99.02%
YARW Yarrow Bioscience	83.78%

Insider Ownership

Company	Insider Ownership
EBS Emergent Biosolutions	6.00%
IMRX Immuneering	14.90%
MYGN Myriad Genetics	1.90%
YARW Yarrow Bioscience	3.03%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EBS Emergent Biosolutions	2,420	51.27 million	48.20 million	Optionable
IMRX Immuneering	60	64.70 million	55.06 million	Not Optionable
MYGN Myriad Genetics	2,700	95.65 million	93.83 million	Optionable
YARW Yarrow Bioscience	30	2.67 million	2.59 million	N/A

YARW, IMRX, EBS, and MYGN Headlines

Recent News About These Companies

40,697 Shares in Yarrow Bioscience $YARW Purchased by Two Sigma Securities LLC

September 7 at 5:04 AM | marketbeat.com

Yarrow Bioscience’s YB-101 Trial Targets Graves’ Disease, Raising New Investor Interest

September 4, 2026 | tipranks.com

Yarrow Bioscience (NASDAQ:YARW) Sees Large Growth in Short Interest

September 3, 2026 | americanbankingnews.com

Analyst Maintains Buy on Yarrow Bioscience, Sees Attractive Risk-Reward with Unchanged $56 Price Target

August 13, 2026 | tipranks.com

Yarrow Bioscience Alters Capital Structure With Warrant Exchange

July 30, 2026 | tipranks.com

Yarrow Bioscience Completes VYNE Therapeutics Merger, Begins Phase 2 Trial Dosing for YB-101

July 29, 2026 | finance.yahoo.com

Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves ...

July 27, 2026 | finance.yahoo.com

VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience

July 23, 2026 | globenewswire.com

VYNE Therapeutics Inc.: VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with ...

July 22, 2026 | finanznachrichten.de

VYNE Therapeutics (NASDAQ:VYNE) Draws Technical Attention After Reverse Split Update

July 22, 2026 | kalkinemedia.comK

VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience

July 21, 2026 | globenewswire.com

Vyne Therapeutics (NASDAQ:VYNE): What’s Behind the Special Dividend?

July 10, 2026 | kalkinemedia.comK

VYNE Therapeutics Announces Special Cash Dividend in Connection with Pending Merger with Yarrow Bioscience

July 10, 2026 | quiverquant.comQ

VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience

July 10, 2026 | globenewswire.com

VYNE Therapeutics Insider Trading Activity | NASDAQ:VYNE | Benzinga

July 1, 2026 | benzinga.com

VYNE Therapeutics (VYNE) price target decreased by 38.46% to 2.04

May 15, 2026 | msn.com

Shareholder Alert: The Ademi Firm investigates whether VYNE Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

December 18, 2025 | prnewswire.com

3 penny stocks to watch now, 12/18/25

December 18, 2025 | msn.com

VYNE to merge with Yarrow in $200 million deal

December 18, 2025 | thepharmaletter.comT

Roundup: Harbor BioMed Announces Collaboration and License Agreement with Bristol Myers, Squibb, VYNE Therapeutics Enters Merger Agreement with Yarrow Bioscience

December 17, 2025 | pharmexec.comP

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of VYNE Therapeutics Inc. (NASDAQ: VYNE)

December 17, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

YARW, IMRX, EBS, and MYGN Company Descriptions

Emergent Biosolutions NYSE:EBS

$5.66 -0.34 (-5.58%)

Closing price 03:59 PM Eastern

Extended Trading

$5.68 +0.01 (+0.26%)

As of 06:09 PM Eastern

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Immuneering NASDAQ:IMRX

$4.61 -0.17 (-3.56%)

Closing price 04:00 PM Eastern

Extended Trading

$4.64 +0.02 (+0.54%)

As of 06:06 PM Eastern

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Myriad Genetics NASDAQ:MYGN

$3.19 +0.01 (+0.31%)

Closing price 04:00 PM Eastern

Extended Trading

$3.18 0.00 (-0.16%)

As of 04:15 PM Eastern

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Yarrow Bioscience NASDAQ:YARW

$29.11 -0.19 (-0.65%)

Closing price 04:00 PM Eastern

Extended Trading

$29.20 +0.09 (+0.31%)

As of 04:10 PM Eastern

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest YARW, IMRX, EBS, and MYGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest YARW, IMRX, EBS, and MYGN Earnings

Compare Dividends

Latest YARW, IMRX, EBS, and MYGN Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

YARW, IMRX, EBS, and MYGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

YARW, IMRX, EBS, and MYGN Company Descriptions

Emergent Biosolutions NYSE:EBS

Immuneering NASDAQ:IMRX

Myriad Genetics NASDAQ:MYGN

Yarrow Bioscience NASDAQ:YARW

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest YARW, IMRX, EBS, and MYGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest YARW, IMRX, EBS, and MYGN Earnings

Compare Dividends

Latest YARW, IMRX, EBS, and MYGN Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

YARW, IMRX, EBS, and MYGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

YARW, IMRX, EBS, and MYGN Company Descriptions

Emergent Biosolutions NYSE:EBS

Immuneering NASDAQ:IMRX

Myriad Genetics NASDAQ:MYGN

Yarrow Bioscience NASDAQ:YARW

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools